Evidence map›Paper›PMID 42892653›Full record

ArticleOncogene2026

Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy.

Yuma Fukumoto, Fumiaki Mukohara, Momoko Iwatsuru, Youki Ueda, Hiroaki Kanzaki, Sadahisa Ogasawara, Jason Lin, Masahito Kawazu, Toshifumi Ninomiya, Naoya Kemmotsu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuma Fukumoto *Department of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Fumiaki Mukohara *Department of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.ORCID http://orcid.org/0009-0000-8866-0684
Momoko IwatsuruDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Youki UedaDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.ORCID http://orcid.org/0000-0002-2627-8524
Hiroaki KanzakiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Jason LinDivision of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
Masahito KawazuDivision of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.ORCID http://orcid.org/0000-0003-4146-3629
Toshifumi NinomiyaDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Naoya KemmotsuDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Joji NagasakiDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Shinichi ToyookaDepartment of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University, Okayama, Japan.
Tsuyoshi OsawaDivision of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9479-6665
Takamasa IshinoDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. t.ishino.0826@gmail.com.ORCID http://orcid.org/0000-0002-8601-0677
Yosuke TogashiDepartment of Tumor Microenvironment, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. ytogashi1584@gmail.com.ORCID http://orcid.org/0000-0001-9910-0164

Funding

Japan Agency for Medical Research and Development (AMED) JP22gm1810002s0101Japan Agency for Medical Research and Development (AMED) JP23ama221325h0001Japan Agency for Medical Research and Development (AMED) JP24ama221336h0001Japan Agency for Medical Research and Development (AMED) JP24fk0210158h0001MEXT | Japan Science and Technology Agency (JST) ACT-X, JPMJAX2321MEXT | Japan Society for the Promotion of Science (JSPS) 24K22071MEXT | Japan Society for the Promotion of Science (JSPS) JP24K11153MEXT | Japan Society for the Promotion of Science (JSPS) JP 24K18933
6 · The paper itself

Abstract

The combination immunotherapies, including those with atezolizumab and bevacizumab (Atez/Bev), have become standard therapy for hepatocellular carcinoma (HCC). However, its efficacy remains limited and reliable biomarkers are lacking. In this study, we analyzed paired tumor and background liver tissues from Atez/Bev-treated HCC patients and found that high programmed cell death-1 (PD-1) expression in CD8

Identifiers

PMID42892653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.